Table 2.
Distance matrix for VP7 and VP4 based on nucleotide and amino acid similarities.
| Nucleotide identity % (amino acid identity %)a | ||||||||
|---|---|---|---|---|---|---|---|---|
| G1-Rotarix® | G1-RotaTeq® | G2-RotaTeq® | G3-RotaTeq® | G4-RotaTeq® | G3-RV3 | G9-116E | ||
| VP7 | Breakthrough G1 | 94.1–94.4 (94.6–95.0) | 91.7–92.0 (93.7–94.0) | 74.3–74.6 (76.0) | 75.1–75.2 (80.1–80.4) | 76.2–76.8 (76.0–76.3) | 74.6–74.8 (80.8–81.1) | 75.7–76.0 (77.6–77.9) |
| Non-breakthrough G1 | 93.9–97.9 (94.3–97.8) | 91.1–93.0 (93.1–95.3) | 73.7–74.8 (75.1–76.3) | 74.9–75.4 (79.2–80.8) | 75.8–77.0 (76.0–76.7) | 74.3–75.1 (79.8–81.4) | 75.4–76.0 (77.3–78.5) | |
| Breakthrough G2 | 72.9–73.8 (74.4–75.4) | 73.0–73.8 (75.1–76.0) | 93.5–94.3 (94.6–95.6) | 73.7–74.0 (74.4–75.1) | 72.3–72.9 (70.7–71.6) | 73.3–73.8 (75.1–76.0) | 74.2–74.7 (74.1–75.4) | |
| Non-breakthrough G2 | 72.8–73.8 (74.4–75.1) | 72.9–73.7 (74.8–75.7) | 93.5–93.8 (95.0–95.6) | 73.5–74.1 (74.1–75.1) | 72.2–73.0 (71.0–71.6) | 73.0–73.9 (74.8–76.0) | 73.9–74.7 (74.4–75.4) | |
| Breakthrough G4 | 75.8–76.2 (76.7–77.4) | 75.2–75.6 (75.5–76.1) | 71.7–72.1 (72.3–73.0) | 74.2–74.5 (74.8–75.2) | 94.8–95.2 (95.3–96.2) | 74.7–74.9 (75.2–75.5) | 74.3–74.6 (77.0–77.8) | |
| Non-breakthrough G4 | 75.8–76.3 (76.7–77.4) | 75.2–75.6 (75.5–76.1) | 71.7–72.3 (72.3–73.0) | 74.2–74.5 (75.2) | 94.8–95.3 (95.3–96.5) | 74.7–75.2 (75.5) | 74.4–74.7 (77.0–77.7) | |
| Breakthrough G9 | 75.8–76.8 (81.1–81.7) | 74.8–76.0 (80.4–81.1) | 75.2–75.7 (78.9–79.2) | 79.3–79.6 (86.1–86.4) | 74.4–75.2 (79.2–79.8) | 78.1–78.4 (86.8–87.4) | 88.2–88.9 (91.5–92.4) | |
| Non-breakthrough G9 | 75.6–76.7 (80.8–81.4) | 74.6–76.0 (80.1–81.1) | 74.9–75.6 (78.5–79.2) | 79.2–79.8 (85.8–86.4) | 74.4–75.5 (79.2–79.8) | 78.1–78.8 (86.8–87.4) | 87.8–88.5 (91.5–92.4) | |
| P[8]-Rotarix® | P[8]-RotaTeq® | |||||||
| VP4 | Breakthrough P[8] | 88.6–90.7 (90.0–94.3) | 88.8–93.5 (90.8–95.4) | |||||
| Non-breakthrough P[8] | 88.4–91.2 (90.0–94.8) | 88.4–93.5 (90.6–95.9) | ||||||
| Breakthrough P[4] | 85.5–86.3 (87.3–87.8) | 85.7–86.1 (88.6–89.5) | ||||||
| Non-breakthrough P[4] | 85.8–86.3 (87.3–88.0) | 85.7–86.1 (88.9–89.7) | ||||||
a
Percent nucleotide and amino acid identities of VP4 (reading frame sequences 49–1422) and VP7 (reading frame sequences 1–951) genes of the Lebanese RVA strains were compared to Rotarix® and RotaTeq® vaccine strains as well as to potential neonatal RV vaccine strains.